Frauenheilkunde up2date 2009; 3(3): 175-195
DOI: 10.1055/s-0029-1224514
Geburtshilfe und Perinatalmedizin

© Georg Thieme Verlag KG Stuttgart ˙ New York

Eklampsie und HELLP-Syndrom[1]

G. Knichwitz, W. Klockenbusch
Further Information

Publication History

Publication Date:
29 June 2009 (online)

Einleitung

Die Inzidenz und der Stellenwert der schwangerschaftsbedingten Erkrankungen (Gestosen) unterscheiden sich nach Region und Entwicklung des Gesundheitssystems erheblich. Die Müttersterblichkeit liegt nach Angaben der WHO in westlichen Ländern bei 1 : 4 000, in Asien bei 1 : 132 und in Afrika bei 1 : 19. Weltweit sind etwa 60 000 Frauen pro Jahr betroffen [65].

Die hierfür in den Industrienationen hauptsächlich verantwortlichen schwangerschaftsbedingten Erkrankungen sind insbesondere die hypertensiven Erkrankungen mit ihren schweren Komplikationen

schwere Präeklampsie, Eklampsie und HELLP-Syndrom.

Die Terminologie dieser Erkrankungen ist bis heute noch uneinheitlich, da die Ätiologie weiterhin unklar ist. Im folgenden Text werden die schwangerschaftsinduzierte Hypertonie, die Präeklampsie, die Eklampsie und das HELLP-Syndrom aufgrund ihrer ätiologischen Gemeinsamkeiten zusammen besprochen.

1 Mod. nach Erstpublikation in Intensivmedizin up2date 2008; 4: 113–133

Literatur

  • 1 American College of Obstetricians and Gynecologists. Hypertension in pregnancy The Committee on Terminology of the American College of Obstetricians and Gynecologists. Washington, DC.  Am Coll Obstet Gynecol. 1996;  53 175-183
  • 2 American CoOaG. 77: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002.  Int J Gyn Obstet. 2002;  77 67-75
  • 3 Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy.  Am J Obstet Gynecol. 1982;  142 159-167
  • 4 National High Blood Pressure Education Program Working Group . Report on high blood pressure in pregnancy.  Am J Obst Gynecol. 1990;  163 1689-1712
  • 5 Cook D J, Sibbald W J, Vincent J -L et al. Evidence based critical care medicine: what is it and what can it do for us?.  Crit Care Med. 1996;  24 334-337
  • 6 Afifi Y, Churchill D. Pharmacological treatment of hypertension in pregnancy.  Curr Pharm Des. 2003;  9 1745-1753
  • 7 Sibai B M. Diagnosis and management of gestational hypertension and preclampsia.  Obstet Gynecol. 2003;  102 181-192
  • 8 Welsch H, Krone H A. Mütterliche Mortalität bei HELLP-Syndrom in Bayern 1983–1992.  Zentralbl Gynäkol. 1994;  116 202-206
  • 9 Sibai B M, Caritis S N, Thom E et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women.  N Engl J Med. 1993;  329 1213-1218
  • 10 CLASP. A randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9 364 pregnant women.  Lancet. 1994;  343 619-629
  • 11 Douglas K A, Redman C WG. Eclampsia in the United Kingdom.  Brit Med J. 1994;  309 1395-1400
  • 12 Sibai B M. Eclampsia – VI. Maternal – perinatal outcome in 254 consecutive cases.  Am J Obstet Gynecol. 1990;  163 1049-1055
  • 13 Rath W. Agressives versus konservatives Vorgehen beim HELLP-Syndrom – eine Standortbestimmung.  Geburtsh Frauenheilk. 1996;  56 265-271
  • 14 Reubinoff B E, Schenker J G. HELLP syndrome – a syndrome of hemolysis, elevated liver enzymes and low platelet count – complicating preeclampsia-eclampsia.  Int J Gynecol Obstet. 1991;  36 95-102
  • 15 Sibai B M, Ramadan M K, Usta I et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome).  Am J Obstet Gynecol. 1993;  169 1000-1006
  • 16 Boxer L M, Malinow A M. Pre-eclampsia and eclampsia.  Current Opin Anaesthesiol. 1997;  10 188-198
  • 17 Roberts J M, Cooper D W. Pathogenesis and genetics of preeclampsia.  Lancet. 2001;  357 53-56
  • 18 Sibai B M, Gordon T, Thom E et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study.  Am J Obstet Gynecol. 1995;  172 642-648
  • 19 Stone J L, Lockwood C J, Berkowitz G S et al. Risk factors for severe preeclampsia.  Obstet Gynecol. 1994;  83 357-361
  • 20 Dekker G A, Van Geijn H P. Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives.  J Perinatol Med. 1996;  24 99-117
  • 21 Frey L. Gestose und HELLP-Syndrom.  Anaesthesist. 1997;  46 732-747
  • 22 Knichwitz G, Louwen F. Intensivmedizin in der Schwangerschaft. In: Van Aken H, Reinhart K, Zimpfer M, Hrsg. Intensivmedizin. Stuttgart, New York: Thieme; 2001: 1299–1313
  • 23 Knichwitz G, Prien T. Intensivmedizinische Aspekte bei Präeklampsie – Eklampsie.  Anästhesiol Intensivmed Notfallmed Schmerzther. 1991;  26 342-346
  • 24 Ballegeer V C, Spitz B, De Baene L A et al. Platelet activation and vascular damage in gestational hypertension.  Am J Obstet Gynecol. 1992;  166 629-633
  • 25 Friedman S A, De Groot C JM, Taylor R N et al. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation.  Am J Obstet Gynecol. 1994;  170 838-841
  • 26 Davidge S T, Signorella A P, Hubel C A et al. Distinct factors in plasma of preeclamptic women increase endothelial nitric oxide or prostacyclin.  Hypertension. 1996;  28 758-764
  • 27 Tsukimori K, Maeda H, Shingu M et al. Possible mechanism of vascular damage in pre-eclampsia.  J Human Hypertension. 1994;  8 177-180
  • 28 Friedman S A. Preeclampsia: a review of the role of prostaglandins.  Obstet Gynecol. 1988;  71 122-137
  • 29 Davidge S T, Hubel C A, Brayden R D et al. Sera antioxidant activity in uncomplicated and preeclamptic pregnancies.  Obstet Gynecol. 1992;  79 897-901
  • 30 Wang Y, Walsh S W, Guo J, Zhang J. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood.  Am J Obstet Gynecol. 1991;  165 1695-1700
  • 31 Mastrogiannis D S, O'Brian W F, Krammer J et al. Potential role of endothelin-1 in normal and hypertensive pregnancies.  Am J Obstet Gynecol. 1991;  165 1711-1716
  • 32 Myatt L, Brewer A S, Langdon G et al. Attenuation of vasoconstrictor effects of thromboxane and endothelin by nitric oxide in the human fetal-placental circulation.  Am J Obstet Gynecol. 1992;  166 224-230
  • 33 Brown M A, Zammit V C, Mitar D M. Extracellular fluid volumes in pregnancy-induced hypertension.  J Hypertension. 1992;  10 61-68
  • 34 Hays P M, Cruikshank D P, Dunn L J. Plasma volume determination in normal and preeclamptic pregnancies.  Am J Obstet Gynecol. 1985;  151 985-966
  • 35 Mushambi M C, Halligan A W, Williamson K. Recent developments in the pathophysiology and management of pre-eclampsia.  Brit J Anaesth. 1996;  76 133-148
  • 36 Visser W, Wallenburg H CS. Central hemodynamic observation in untreated preeclamptic patients.  Hypertension. 1991;  17 1072-1077
  • 37 Royburt M, Seidman D, Serr D et al. Neurologic involvement in hypertensive disease of pregnancy.  Obstet Gynecol. 1991;  46 656-661
  • 38 Seidman D S, Sen D M, Ben-Rafael Z. Renal and ocular manifestations of hypertensive diseases of pregnancy.  Obstet Gynecol. 1991;  46 71-78
  • 39 Sibai B M, Mabie B C, Harvey C J et al. Pulmonary edema in severe preeclampsia-eclampsia: Analysis of thirty-seven consecutive cases.  Am J Obstet Gynecol. 1987;  156 1174-1179
  • 40 Desai D K, Moodley J, Naidoo D P et al. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy.  Brit J Obstet Gynaecol. 1996;  103 523-528
  • 41 Schiff E, Friedman S A, Kao L et al. The importance of urinary protein excretion during conservative management of severe preeclampsia.  Am J Obstet Gynecol. 1996;  175 1313-1316
  • 42 Chua S, Redman C W. Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours.  Eur J Obstet Gynecol Reprod Biol. 1992;  43 9-12
  • 43 Wolf J L. Liver desease in pregnancy.  Med Clin North Am. 1996;  80 1167-1187
  • 44 Salfelder A, Kagerah M, Nugent W et al. Diagnostische Probleme beim HELLP-Syndrom – dargestellt anhand von 20 Fallbeispielen.  Zentralbl Gynäkol. 1993;  115 433-445
  • 45 Rath W, Loos W, Kuhn W. Diagnostische und therapeutische Probleme beim HELLP-Syndrom.  Z Geburtsh Perinatol. 1992;  196 185-192
  • 46 Wilke G, Rath W, Schutz E et al. Haptoglobin as a sensitive marker of hemolysis in HELLP-syndrome.  Int J Gynecol Obstet. 1992;  39 29-34
  • 47 Rath W, Loos W, Graeff H et al. Das HELLP-Syndrom.  Gynäkologe. 1992;  25 430-440
  • 48 Martin J N, Blake P G, Perry K G et al. The natural history of HELLP syndrome: patterns of disease progression and regression.  Am J Obstet Gynecol. 1991;  164 1500-1513
  • 49 Knox T A, Olans L B. Liver disease in pregnancy.  N Engl J Med. 1996;  335 569-576
  • 50 Schwartz M L, Lien J M. Spontaneous liver hematoma in pregnancy not clearly associated with preeclampsia: A case presentation and literature review.  Am J Obstet Gynecol. 1997;  176 1328-1333
  • 51 Neiger R, Contag S A, Coustan D R. The resolution of preeclampsia-related thrombocytopenia.  Obstet Gynecol. 1991;  77 692-695
  • 52 Rath W, Wieding J U, Kuhn W. Neue Erkenntnisse über hämostasiologische Veränderungen bei Gestose und HELLP-Syndrom für die klinische Praxis.  Geburtsh Frauenheilk. 1991;  51 741-746
  • 53 Nolan T E, Wakefield M L, Devoe L D. Invasive hemodynamic monitoring in obstetrics. A critical review of its indications, benefits, complications, and alternatives.  Chest. 1992;  101 1429-1433
  • 54 Sibai B M, Mercer B M, Schiff E et al. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks gestation: a randomized controlled trial.  Am J Obstet Gynecol. 1994;  171 818-822
  • 55 Visser W, Wallenburg H CS. Temporising management of severe pre-eclampsia with and without the HELLP-syndrome.  Brit J Obstet Gynaecol. 1995;  102 111-117
  • 56 Toppozada M K. Role of prostaglandins in pre-eclampsia.  Acta obstet gynecol scand. 1990;  69 375-377
  • 57 Fox J G, Sutcliffe N P, Walker J J et al. Postpartum eclampsia and acut renal failure: treatment with prostacyclin. Case report.  Brit J Obstet Gynaecol. 1991;  98 400-402
  • 58 Beaufils M, Uzan S, Donsimoni R et al. Prevention of preeclampsia by early antiplatelet therapy.  Lancet. 1985;  1 840-842
  • 59 Wallenburg H CS, Dekker G A, Makovitz J W et al. Low-dose-aspirin prevents pregnancy induced hypertension and preeclampsia in angiotensin sensitive primigravidae.  Lancet. 1986;  1 1-3
  • 60 Benedetti T J, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema.  Am J Obstet Gynecol. 1985;  152 330-334
  • 61 Friedman S A, Kee-Hak L, Baker C A et al. Phenytoin versus magnesium sulphate in pre-eclampsia: a pilot study.  Am J Perinatol. 1993;  10 233-238
  • 62 The ETCG. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial.  Lancet. 1995;  345 1455-1463
  • 63 Sibai B M. Magnesium sulfate is the ideal anticonvulsant in preeclampsia-eclampsia.  Am J Obstet Gynecol. 1990;  162 1141-1145
  • 64 Sibai B M. Diagnosis and management of gestational hypertension and preeclampsia.  Obstet Gynecol. 2003;  102 181-192
  • 65 Hill K. Making deaths count.  Bull World Health Organ. 2006;  84 162
  • 66 Duley L, Henderson-Smart D J, Meher S et al. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659
  • 67 Duley L, Henderson-Smart D J, Meher S et al. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007; 18: CD004659
  • 68 Ganzevoort W, Rep A, Bonsel G J et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia.  Brit J Obstet Gynaecol. 2005;  112 1358-1368
  • 69 The Magpie Trial Collaborative Group . Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial. A randomised, placebo-controlled trial.  Lancet. 2002;  359 1877-1890
  • 70 Magee L, Miremadi S, Li J et al. Therapy with both magnesium sulphate and nifedipine does not increase the risk of serious magnesium-related maternal side-effects in women with preeclampsia.  Am J Obstet Gynecol. 2005;  193 153-163
  • 71 Magee L A, Cham C, Waterman E J et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.  Brit Med J. 2003;  327 955-960
  • 72 Duley L, Galmezoglu A M, Henderson-Smart D J. Magnesium sulfate and other anticonvulsants for women with preeclampsia. Cochrane Database Syst Rev 2003; 2: CD000025

1 Mod. nach Erstpublikation in Intensivmedizin up2date 2008; 4: 113–133

Prof. Dr. med. G. Knichwitz

Abteilung für Anästhesiologie, Intensivmedizin und Schmerztherapie Malteser-Krankenhaus Bonn/Rhein-Sieg

Von-Hompesch-Str. 1

53123 Bonn

Email: knichwi@uni-muenster.de


Weiterführende Literatur
AWMF-Leitlinien-Register Nr. 015 / 018.
www.leitlinien.net

    >